Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6564 participants.
Also called NCT02504216
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 6,564 participants
- Registry
-
NCT02504216 -
2014-005569-58
-
- Other papers using this trial's data
- Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial
- Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD Trial
- Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety
- Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD
- Rivaroxaban in Peripheral Artery Disease after Revascularization
- Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits
- Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD
- Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD
- Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, Estonia, Finland, France, Germany, Hungary, Italy, Japan, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02504216. Randomized; quadruple masking; primary purpose prevention. Start 2015-08-18 (actual); primary completion 2019-11-27 (actual). Results posted on 2020-12-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
- Acronym
- VOYAGER PAD
- Condition
- Peripheral Artery Disease
- Intervention (Drug)
- Rivaroxaban (Xarelto, BAY59-7939)
- Intervention (Drug)
- Rivaroxaban-Placebo
- Lead sponsor
- Bayer
- Collaborator
- Janssen Research & Development, LLC
- Collaborator
- Colorado Prevention Center
Record details
- Record id
cardio:ct-nct02504216- Content hash
841e6712a185a9d24c82537994d7d78a0c3e17873d505a63b4c3d2e519f89176